A clinical-pathological study on chronic hepatitis in Auckland

Area of Science:

• Hepatology
• Immunology
• Public Health

Background:

• Chronic hepatitis represents a significant liver disease burden.
• Understanding the demographics and subtypes of chronic hepatitis is crucial for effective management.
• Hepatitis B virus (HBV) infection is a major global health concern, particularly in certain ethnic groups.

Purpose of the Study:

• To analyze liver histology and clinical data of patients diagnosed with chronic hepatitis.
• To investigate the prevalence of different chronic hepatitis subtypes and their association with patient demographics.
• To explore the link between chronic hepatitis B infection, ethnicity, and hepatocellular carcinoma risk.

Main Methods:

• Prospective analysis of liver histology and clinical data from 45 chronic hepatitis patients.
• Categorization of hepatitis into chronic active hepatitis and chronic persistent hepatitis.
• Examination of demographic data, including ethnicity and gender, in relation to hepatitis subtypes.

Main Results:

• Chronic active hepatitis was more common than chronic persistent hepatitis.
• Hepatitis B virus infection accounted for 38% of cases, with 53% of these in Maori or Polynesian individuals.
• A high prevalence of hepatitis B surface antigen carriers and hepatocellular carcinoma was observed in Maori and Polynesian populations.
• Lupoid hepatitis, characterized by immunological abnormalities, was observed in 5 patients and all were women.
• Patients with chronic persistent hepatitis generally showed less severe biochemical liver function test abnormalities.

Conclusions:

• Chronic hepatitis B infection disproportionately affects Maori and Polynesian populations, aligning with high carrier rates and hepatocellular carcinoma incidence.
• Lupoid hepatitis, a small subgroup with immunological abnormalities, shows potential for steroid treatment response.
• Further research is needed to elucidate the specific factors contributing to ethnic disparities in hepatitis B outcomes.